Last reviewed · How we verify

Pilocarpine HCl — Competitive Intelligence Brief

Pilocarpine HCl (Pilocarpine HCl) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscarinic receptor agonist. Area: Ophthalmology / Otolaryngology.

phase 3 Muscarinic receptor agonist Muscarinic M3 receptor Ophthalmology / Otolaryngology Small molecule Live · refreshed every 30 min

Target snapshot

Pilocarpine HCl (Pilocarpine HCl) — Allergan. Pilocarpine HCl is a muscarinic acetylcholine receptor agonist that stimulates parasympathetic activity to increase salivary and lacrimal gland secretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pilocarpine HCl TARGET Pilocarpine HCl Allergan phase 3 Muscarinic receptor agonist Muscarinic M3 receptor
Aclidinium bromide/formoterol fumarate combination Aclidinium bromide/formoterol fumarate combination AstraZeneca marketed Long-acting anticholinergic/long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor and beta-2 adrenergic receptor
umeclidinium 62.5 µg and vilanterol 25 µg umeclidinium 62.5 µg and vilanterol 25 µg University of Tennessee Graduate School of Medicine marketed Long-acting anticholinergic and long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor (umeclidinium); Beta-2 adrenergic receptor (vilanterol)
umeclidinium bromide (UMEC) umeclidinium bromide (UMEC) GlaxoSmithKline marketed Long-acting muscarinic antagonist (LAMA) Muscarinic M3 receptor
FF/UMEC/VI FF/UMEC/VI Dr. Grace Parraga marketed Triple combination inhaler (ICS/LAMA/LABA) Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
UMEC/VI DPI UMEC/VI DPI GlaxoSmithKline marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor (umeclidinium); Beta-2 adrenergic receptor (vilanterol)
Salbutamol + Tiotropium Salbutamol + Tiotropium IRCCS Azienda Ospedaliero-Universitaria di Bologna marketed Combination bronchodilator (short-acting beta-2 agonist + long-acting anticholinergic) Beta-2 adrenergic receptor (salbutamol); Muscarinic M3 receptor (tiotropium)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscarinic receptor agonist class)

  1. Allergan · 1 drug in this class
  2. LENZ Therapeutics, Inc · 1 drug in this class
  3. Maastricht University Medical Center · 1 drug in this class
  4. Ocuphire Pharma, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pilocarpine HCl — Competitive Intelligence Brief. https://druglandscape.com/ci/pilocarpine-hcl. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: